The funding takes Istesso’s latest round to $13m as the company continues clinical trials on an immunometabolic drug licensed from an Aberdeen spinout in 2007.
Istesso, a UK-based immuno-metabolism drug developer with links to University of Aberdeen research, extended its latest funding round to £10m ($13m) on Friday with a £4m ($5.2m) contribution from undisclosed investors. The additional tranche follows an initial close in December 2018 backed by commercialisation firm IP Group, its fund management division Parkwalk Advisors and venture…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
